On September 20, 2024, BioNTech SE and Pfizer announced that the European Medicines Agency's CHMP recommended marketing authorization for their Omicron KP.2-adapted COVID-19 vaccine (COMIRNATY ® KP.2) for individuals 6 months and older.
AI Assistant
BIONTECH SE
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.